ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatm…
Biotechnology
US, South San Francisco [HQ]
Document Reader
Link Index · Filing Reader · 10K/10QThis analysis tool lets you read the documents of ALX Oncology Holdings Inc.
DEF 14-A Proxies
10-Ks
10-Qs
Not a single 10-Q doc.
LDA 1/2s
Click To Read:
DEF 14-A Proxies
Not a single DEF 14-A proxy doc.
10-K Filings
Not a single 10-K doc.
10-Q Filings
Not a single 10-Q doc.
LDA 1/2 Filings [Lobbying]
Not a single LDA doc.